Literature DB >> 20859193

Contemporary costs of HIV healthcare in the HAART era.

Kelly A Gebo1, John A Fleishman, Richard Conviser, James Hellinger, Fred J Hellinger, Joshua S Josephs, Philip Keiser, Paul Gaist, Richard D Moore.   

Abstract

BACKGROUND: The delivery of HIV healthcare historically has been expensive. The most recent national data regarding HIV healthcare costs were from 1996-1998. We provide updated estimates of expenditures for HIV management.
METHODS: We performed a cross-sectional review of medical records at 10 sites in the HIV Research Network, a consortium of high-volume HIV care providers across the United States. We assessed inpatient days, outpatient visits, and prescribed antiretroviral and opportunistic illness prophylaxis medications for 14 691 adult HIV-infected patients in primary HIV care in 2006. We estimated total care expenditures, stratified by the median CD4 cell count obtained in 2006 (≤50, 51-200, 201-350, 351-500, >500 cells/μl). Per-unit costs of care were based on Healthcare Cost and Utilization Project (HCUP) data for inpatient care, discounted average wholesale prices for medications, and Medicare physician fees for outpatient care.
RESULTS: Averaging over all CD4 strata, the mean annual total expenditures per person for HIV care in 2006 in three sites was US $19 912, with an interquartile range from US $11 045 to 22 626. Average annual per-person expenditures for care were greatest for those with CD4 cell counts 50 cell/μl or less (US $40 678) and lowest for those with CD4 cell counts more than 500 cells/μl (US $16 614). The majority of costs were attributable to medications, except for those with CD4 cell counts 50 cells/μl or less, for whom inpatient costs were highest.
CONCLUSION: HIV healthcare in the United States continues to be expensive, with the majority of expenditures attributable to medications. With improved HIV survival, costs may increase and should be monitored in the future.

Entities:  

Mesh:

Year:  2010        PMID: 20859193      PMCID: PMC3551268          DOI: 10.1097/QAD.0b013e32833f3c14

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  36 in total

1.  Providing antiretroviral therapy for HIV infection.

Authors:  R Steinbrook
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

2.  Estimating log models: to transform or not to transform?

Authors:  W G Manning; J Mullahy
Journal:  J Health Econ       Date:  2001-07       Impact factor: 3.883

3.  Trends in HIV-related inpatient admissions from 1993 to 1997: a seven-state study.

Authors:  J A Fleishman; F J Hellinger
Journal:  J Acquir Immune Defic Syndr       Date:  2001-09-01       Impact factor: 3.731

4.  Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy.

Authors:  S A Bozzette; G Joyce; D F McCaffrey; A A Leibowitz; S C Morton; S H Berry; A Rastegar; D Timberlake; M F Shapiro; D P Goldman
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

5.  Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy.

Authors:  K A Gebo; M Diener-West; R D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

6.  Hospital and outpatient health services utilization among HIV-infected patients in care in 1999.

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2002-05-01       Impact factor: 3.731

7.  Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.

Authors:  L Martín-Carbonero; V Soriano; E Valencia; J García-Samaniego; M López; J González-Lahoz
Journal:  AIDS Res Hum Retroviruses       Date:  2001-11-01       Impact factor: 2.205

8.  Recent trends in HIV-related inpatient admissions 1996-2000: a 7-state study.

Authors:  John A Fleishman; Fred H Hellinger
Journal:  J Acquir Immune Defic Syndr       Date:  2003-09-01       Impact factor: 3.731

9.  The healthcare cost and utilization project: an overview.

Authors:  Claudia Steiner; Anne Elixhauser; Jenny Schnaier
Journal:  Eff Clin Pract       Date:  2002 May-Jun

10.  Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Authors:  Kelly A Gebo; Marie Diener-West; Richard D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2003-10-01       Impact factor: 3.731

View more
  66 in total

1.  Protease Inhibitors for Patients With HIV-1 Infection: A Comparative Overview.

Authors:  Peter J Hughes; Erika Cretton-Scott; Ami Teague; Terri M Wensel
Journal:  P T       Date:  2011-06

2.  An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.

Authors:  Nicholas Pagano; Peter Teriete; Margrith E Mattmann; Li Yang; Beth A Snyder; Zhaohui Cai; Marintha L Heil; Nicholas D P Cosford
Journal:  Bioorg Med Chem       Date:  2017-04-08       Impact factor: 3.641

3.  Evaluation of a Computer-Based HIV Education Program for Adults Living with HIV.

Authors:  Shrinidhi Subramaniam; Carol-Ann Getty; August F Holtyn; Andrew Rodewald; Brian Katz; Brantley P Jarvis; Jeannie-Marie S Leoutsakos; Michael Fingerhood; Kenneth Silverman
Journal:  AIDS Behav       Date:  2019-11

4.  Antiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.

Authors:  Bohdan Nosyk; Julio S G Montaner; Benita Yip; Viviane D Lima; Robert S Hogg
Journal:  Med Care       Date:  2014-04       Impact factor: 2.983

5.  The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Authors:  Blythe Adamson; Wafaa El-Sadr; Dobromir Dimitrov; Theresa Gamble; Geetha Beauchamp; Josh J Carlson; Louis Garrison; Deborah Donnell
Journal:  Value Health       Date:  2018-11-02       Impact factor: 5.725

6.  Chronic health conditions in Medicare beneficiaries 65 years old, and older with HIV infection.

Authors:  Eleanor E Friedman; Wayne A Duffus
Journal:  AIDS       Date:  2016-10-23       Impact factor: 4.177

7.  Costs of health resource utilization among HIV-positive individuals in British Columbia, Canada: results from a population-level study.

Authors:  Bohdan Nosyk; Viviane Lima; Guillaume Colley; Benita Yip; Robert S Hogg; Julio S G Montaner
Journal:  Pharmacoeconomics       Date:  2015-03       Impact factor: 4.981

8.  The Fragility Index in a Cohort of HIV/AIDS Randomized Controlled Trials.

Authors:  Cole Wayant; Chase Meyer; Rebecca Gupton; Mousumi Som; Damon Baker; Matt Vassar
Journal:  J Gen Intern Med       Date:  2019-04-29       Impact factor: 5.128

9.  Expenditures for Persons Living With HIV Enrolled in Medicaid, 2006-2010.

Authors:  John A Fleishman; Anne K Monroe; Cindy C Voss; Richard D Moore; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

10.  Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.

Authors:  Kristen Underhill
Journal:  Am J Law Med       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.